ID
31804
Description
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00631371
Link
https://clinicaltrials.gov/show/NCT00631371
Keywords
Versions (1)
- 9/29/18 9/29/18 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
September 29, 2018
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Renal Cell Carcinoma NCT00631371
Eligibility Renal Cell Carcinoma NCT00631371
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Systemic therapy Renal Cell Carcinoma
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1515119
- UMLS CUI [1,2]
- C0007134
Description
CNS metastases
Data type
boolean
Alias
- UMLS CUI [1]
- C0686377
Description
Cardiovascular Disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0007222
Description
Pregnancy | Breast Feeding
Data type
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Description
Criteria Additional
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0243161
- UMLS CUI [1,2]
- C1524062
Similar models
Eligibility Renal Cell Carcinoma NCT00631371
- StudyEvent: Eligibility
C0205179 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,2])
C0205164 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0007134 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C1524062 (UMLS CUI [1,2])
No comments